Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Products under Development by Indication | 10 | 2 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Products under Development by Companies | 14 | 4 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Products under Development by Universities/Institutes | 18 | 2 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Therapeutics Assessment | 20 | 6 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 26 | 8 |
| Almac Discovery Limited | 26 | 1 |
| ArQule, Inc. | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| Bayer AG | 29 | 1 |
| Merck &Co., Inc. | 30 | 2 |
| Novartis AG | 32 | 1 |
| Rexahn Pharmaceuticals, Inc. | 33 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Drug Profiles | 34 | 24 |
| ALM-301 Drug Profile | 34 | 2 |
| ARQ-092 Drug Profile | 36 | 3 |
| AZD-5363 Drug Profile | 39 | 3 |
| BAY-1001931 Drug Profile | 42 | 1 |
| BAY-1125976 Drug Profile | 43 | 1 |
| MK-2206 Drug Profile | 44 | 3 |
| MK-2206 + selumetinib sulfate Drug Profile | 47 | 1 |
| RX-0201 Drug Profile | 48 | 4 |
| RX-0201N Drug Profile | 52 | 1 |
| Small Molecules to Inhibit AKT1 for Oncology Drug Profile | 53 | 1 |
| Small Molecules to Inhibit Akt1/2 for Oncology Drug Profile | 54 | 1 |
| trametinib dimethyl sulfoxide + uprosertib Drug Profile | 55 | 2 |
| uprosertib Drug Profile | 57 | 1 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Dormant Projects | 58 | 3 |
| RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) Featured News &Press Releases | 61 | 14 |
| Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting | 61 | 1 |
| Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting | 62 | 1 |
| Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data For Archexin-Nano At The 2016 American Association For Cancer Research Annual Meeting | 63 | 1 |
| Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma | 63 | 1 |
| Jan 28, 2016: ArQule Provides Update on ARQ 092 | 64 | 1 |
| Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study | 65 | 2 |
| Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 | 67 | 1 |
| Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 67 | 1 |
| Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium | 68 | 2 |
| Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics | 70 | 1 |
| Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology | 70 | 1 |
| Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference | 71 | 1 |
| May 13, 2015: Rexahn Announces Poster Presentation On RX-0201 at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting | 72 | 1 |
| Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium | 72 | 1 |
| Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |